Abstract 275P
Background
Current treatment for primary central nervous system lymphoma involves high-dose methotrexate based regimen. In low&middle-income countries like Vietnam, a shortage of drugs and monitoring is common. The present study reports the first experience and preliminary results of 25 patients PCNSL treated with HD-MTX and RTX.
Methods
Following Institutional Review Board approval by Vietnam National Institute for Cancer Control, a prospective study evaluating the treatment of histologically confirmed PCNSL with combined biweekly HD-MTX (8g/m2/dose) and weekly RTX (375 mg/m2/dose) for 8 cycles. Responders received consolidation treatment with 2 additional cycles, followed by maintenance with monthly HD-MTX for up to 12 months. Patients received aggressive hydration infusion to maintain a urine output of ≥ 100 ml/h and a urinary pH of > 7, until serum MTX levels had decreased to ≤ 0.1 µM/l. Serum MTX levels were monitored daily. Leucovorin rescue was initiated 24 h after completion of MTX infusion and administered at 50 mg IV every 6 h for the first 4 doses and then 30 mg IV until serum MTX levels were ≤0.1 µM/l. Leucovorin dosing was increased in cases of slow MTX clearance. The primary end point was radiographic response, and drug-related toxicity and secondary were survival.
Results
From 01/2017 to 12/2018, 25 patients were analysed (13 males and 12 females, median age 58.6). Following a mean of 10,72 cycles, the response rate and CR rate was 88% and 36%. The median PFS was 13 months and the OS has not yet been attained. MTX clearance was achieved by 72h in 198/268 cycles, and by 96h in 92%; 30.9% cycles needed escalation of leucovorin rescue dose. Toxicity: transient transaminitis (72%), mucotitis (59%) and diarhea (61.9%), febrile neutropenia (8%). Pneumonia was observed in 2 patients. 4 patients had renal dysfunction and 2 patient had dialysis.
Conclusions
RTX combined HDMTX for PCNSL is possible in lower-middle income countries like Vietnam but should be done in experienced centers capable of close monitoring serum MTX levels to prevent toxicity. The addition of RTX to HD-MTX in the treatment of PCNSL may increase response rates and prolong PFS. The final results currently in progress will more definitively estimate the survival.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
490P - Outcomes of sequential epidermal growth factor receptor tyrosine (EGFR) tyrosine kinase inhibitor (TKI) therapy in patients with advanced non-small cell lung carcinoma (NSCLC)- a real-world institutional experience
Presenter: Yvonne Ang
Session: Poster display session
Resources:
Abstract
498P - An observational retrospective study to evaluate the incidence of acquired EGFR T790M resistance in NSCLC patients with EGFR mutation following progression after at least one prior EGFR TKI treatment in Taiwan: ARISE study
Presenter: Shang-gin Wu
Session: Poster display session
Resources:
Abstract
501P - Clinical characteristics and efficacy in non-small cell lung cancer patients with EGFR exon 20 insertion and EGFR amplification
Presenter: Xin Gao
Session: Poster display session
Resources:
Abstract
502P - Epidermal growth factor receptor tyrosine kinase inhibitor treatment response in advanced non-small cell lung cancer with uncommon mutations: A multicenter observational study
Presenter: Masaki Kanazu
Session: Poster display session
Resources:
Abstract
482P - Interim analysis from a phase IIIb, open-label study of afatinib in EGFR TKI-naïve patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC
Presenter: Filippo De Marinis
Session: Poster display session
Resources:
Abstract
483P - A phase IIIb, open-label study of afatinib in EGFR TKI-naïve patients with EGFR mutation-positive NSCLC: A biomarker analysis
Presenter: Rafael Rosell
Session: Poster display session
Resources:
Abstract
484P - Activity of afatinib in patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC and baseline brain metastases: Pooled analysis of three large phase IIIb trials
Presenter: Maya Gottfried
Session: Poster display session
Resources:
Abstract
491P - Clinical outcomes of leptomeningeal metastases in EGFR-mutant lung adenocarcinoma
Presenter: Chia-I Shen
Session: Poster display session
Resources:
Abstract
510P - Paclitaxel as continuation maintenance therapy in patients with advanced non-small cell lung cancer
Presenter: Suzy Gohar
Session: Poster display session
Resources:
Abstract
496P - Higher osimertinib introduction rate achieved by multiple repeated re-biopsy after acquired resistance to first/second generation EGFR-TKIs
Presenter: Taira Ninomaru
Session: Poster display session
Resources:
Abstract